Wellness and Longevity Medicine
Can Metformin Slow Aging? What New Human Studies Really Show
Metformin is an established diabetes medication and a leading candidate in longevity research. Recent trials offer intriguing biomarker and frailty findings, but no study has shown that it extends life in healthy people.

Metformin has been used to treat type 2 diabetes for decades. It is inexpensive, familiar to clinicians, and supported by extensive safety data in appropriately selected patients. Laboratory research also suggests that it may influence pathways connected with nutrient sensing, inflammation, mitochondrial function, and cellular aging.
Those facts have helped turn metformin into one of the most discussed prescription drugs in longevity medicine. The central question, however, is not whether metformin changes an aging-related laboratory marker. It is whether taking it helps people without diabetes remain healthier or live longer without creating unnecessary harm.
The current answer is straightforward: metformin has not been shown to extend lifespan in healthy people. New human research is interesting, but it does not yet justify prescribing metformin solely as an anti-aging drug.
Why observational studies are not enough
Much of the enthusiasm began with studies of people who had type 2 diabetes. Some reported lower rates of cancer, cardiovascular events, dementia, or death among people taking metformin compared with those using other diabetes treatments.
These comparisons are difficult to interpret. Metformin is often used earlier in diabetes, while insulin and some other drugs may be prescribed after the disease has progressed. Patients receiving different treatments can differ in kidney function, weight, disease severity, access to care, and many other ways that affect outcomes.
A 2023 analysis of health records from Wales followed more than 129,000 people treated with metformin and matched them with people without diabetes. An apparent early survival advantage did not persist during longer follow-up. The study does not prove that metformin shortens life. It shows why short observational comparisons can produce misleading conclusions about longevity.
Randomized trials are more informative, but most completed studies have been too small, too short, or focused on biomarkers rather than lifespan or major age-related diseases.
What the new telomere study found
In September 2026, researchers reported a 24-week randomized trial involving 127 adults in North India who had prediabetes. Participants received metformin 500 mg twice daily or placebo, along with lifestyle counseling. Of those randomized, 112 completed the study.
The metformin group had larger increases in leukocyte telomere length and telomerase activity than the placebo group. The investigators also reported changes in selected gene-expression markers related to longevity.
These findings are biologically interesting, but they are not evidence that participants became younger, avoided disease, or will live longer. Telomere length measured in circulating white blood cells is a surrogate marker. It can vary by cell composition, laboratory method, inflammation, and other factors. A 24-week change cannot establish a durable clinical benefit.
The reported magnitude also deserves independent replication. The study involved one population with prediabetes, not metabolically healthy adults of all backgrounds. It should generate further research rather than a new prescribing standard.
The 2026 frailty trial is promising but preliminary
A July 2026 preprint described a two-year randomized, placebo-controlled trial of 145 older adults with glucose intolerance. Metformin improved a 95-item deficit-accumulation frailty index and two blood-based epigenetic age estimates. It did not improve the study's other major frailty measure, the Fried frailty phenotype.
This distinction matters. Frailty is not a single laboratory value. Different tools capture different aspects of weight loss, strength, walking speed, activity, exhaustion, medical conditions, and functional deficits. A favorable result on one scale but not another is a signal to investigate, not proof that aging was slowed.
The report is also a preprint. It has not completed journal peer review and should not guide clinical practice on its own. The participants had prediabetes or glucose intolerance, so the findings cannot automatically be applied to healthy adults with normal glucose regulation.
Other randomized trials have been neutral or unfavorable
In the 2025 MET-PREVENT trial, 72 older adults with probable sarcopenia and physical frailty or prefrailty received metformin or placebo for four months. Metformin did not improve walking speed, grip strength, muscle mass, physical performance, quality of life, or daily function. More participants stopped metformin, commonly reflecting tolerability challenges in this vulnerable population.
Research has also raised questions about combining metformin with exercise in metabolically healthy older adults. In one randomized study, metformin attenuated average improvements in aerobic fitness, insulin sensitivity, and skeletal-muscle mitochondrial respiration during 12 weeks of exercise training. In another trial, it reduced average muscle growth during resistance training, although responses varied among individuals.
These studies do not establish that metformin broadly cancels the benefits of exercise. They were relatively small and addressed specific populations and training protocols. They do show that a drug can affect healthy physiology in unexpected ways. A medication should not be assumed to add to proven lifestyle benefits simply because it influences an aging pathway in laboratory experiments.
What about the TAME trial?
The proposed Targeting Aging with Metformin, or TAME, program was designed to test whether metformin could delay a composite of major age-related diseases in more than 3,000 adults ages 65 to 79. This would be much closer to the clinical question that matters.
As of October 1, 2026, the American Federation for Aging Research states that the study design is prepared but funding is still needed to launch the trial. Therefore, TAME has not produced evidence that metformin delays aging or extends healthy life.
When metformin may still be appropriate
Metformin remains an important treatment for type 2 diabetes. The American Diabetes Association's 2026 Standards of Care also say it should be considered for diabetes prevention in selected adults at high risk, especially younger adults with substantial obesity, higher fasting glucose or A1C, or a history of gestational diabetes.
That is different from taking metformin solely for longevity. A person with diabetes or high-risk prediabetes may reasonably receive metformin for a metabolic indication. Any downstream effect on long-term health would be an additional research question, not a guaranteed anti-aging benefit.
For a metabolically healthy person, there is no validated test that predicts who would benefit from metformin for aging. An epigenetic clock, telomere test, insulin level, or wearable score cannot establish that the medication will extend that person's life.
Metformin is familiar, but it is not risk-free
The most common adverse effects are gastrointestinal, including diarrhea, nausea, abdominal discomfort, and reduced appetite. Slow dose increases and extended-release formulations may improve tolerance, but they do not make treatment appropriate for everyone.
Long-term use can lower vitamin B12 levels. The 2026 ADA guidance recommends periodic B12 assessment, particularly for people with anemia, neuropathy, higher doses, longer exposure, or other deficiency risks.
Metformin is cleared through the kidneys. The current FDA labeling requires kidney-function assessment and lists severe renal impairment as a contraindication. Metformin-associated lactic acidosis is rare but serious, with higher risk in settings such as significant kidney dysfunction, hypoxic illness, excessive alcohol intake, liver impairment, certain drug interactions, surgery, or selected contrast procedures. Medication instructions around illness, fasting, procedures, and contrast should come from the treating clinician.
The bottom line
Metformin is a valuable metabolic drug and a credible research candidate. Recent trials suggest that it can change some aging-related biomarkers and may affect one measure of frailty in older adults with abnormal glucose regulation. Other trials have found no functional benefit and possible interference with some exercise adaptations.
None has shown that metformin makes healthy people live longer. Until large, adequately powered trials report clinical outcomes, using it solely for longevity remains experimental.
Brainology can help patients review metabolic risk, medications, sleep, exercise, nutrition, and other factors that influence healthy aging. Decisions about metformin should be based on an individualized medical indication and monitoring plan, not a supplement-style longevity claim.
This draft is for educational purposes and is not medical advice. It should receive clinical and editorial review before publication.
References
U.S. Food and Drug Administration. GLUMETZA prescribing information. Revised August 2026.
American Diabetes Association Professional Practice Committee. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes 2026. Diabetes Care. 2026;49(Suppl 1):S50-S60. doi:10.2337/dc26-S003.
Bhatt SP, Pandey S, Misra A. Metformin Therapy Increases Leukocyte Telomere Length, Telomerase Activity, and Longevity Gene Expression in Asian Indians with Prediabetes. Mechanisms of Ageing and Development. 2026:112241. doi:10.1016/j.mad.2026.112241.
Musi N, Wang CP, MacCarthy D, et al. A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance. medRxiv preprint. Posted July 28, 2026. doi:10.64898/2026.07.27.26359055.
Witham MD, McDonald C, Wilson N, et al. Metformin and Physical Performance in Older People with Probable Sarcopenia and Physical Prefrailty or Frailty in England. The Lancet Healthy Longevity. 2025;6(3):100695. doi:10.1016/j.lanhl.2025.100695.
Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin Inhibits Mitochondrial Adaptations to Aerobic Exercise Training in Older Adults. Aging Cell. 2019;18(1):e12880. doi:10.1111/acel.2018.12880.
Walton RG, Dungan CM, Long DE, et al. Metformin Blunts Muscle Hypertrophy in Response to Progressive Resistance Exercise Training in Older Adults. Aging Cell. 2019;18(6):e13039. doi:10.1111/acel.13039.
Stevenson-Hoare J, Leonenko G, Escott-Price V. Comparison of Long-Term Effects of Metformin on Longevity Between People With Type 2 Diabetes and Matched Non-Diabetic Controls. BMC Public Health. 2023;23:804. doi:10.1186/s12889-023-15764-y.
American Federation for Aging Research. Targeting Aging with Metformin Trial. Accessed October 1, 2026.